Somnus Announces Launch of the Elypse(TM) Control Unit

New Smaller-Sized Control Unit Available at Lower Cost



Apr 10, 2001, 01:00 ET from Somnus Medical Technologies Inc.

    SUNNYVALE, Calif., April 10 /PRNewswire/ --
 Somnus Medical Technologies Inc. (Nasdaq:   SOMN), announced today the
 availability of the Elypse Control Unit for the treatment of upper airway
 disorders.
     The Elypse Control Unit is another addition to the Somnoplasty(R)
 platform.  The new Control Unit delivers temperature-controlled radiofrequency
 energy to reduce and tighten tissue in the upper airway.  It is compatible
 with all existing Somnus single-channel handpieces.  In addition, the Control
 Unit has a compact new design.  Its small size makes it easy to transport
 between offices or treatment settings.  The Control Unit will be offered at a
 lower price than Somnus' existing two-channel Control Unit.
     "The new Elypse Control Unit is specifically designed for the office
 setting and should enable us to accelerate our penetration of this market
 segment," said John Schulte, President and CEO of Somnus Medical Technologies,
 Inc.  "It should provide compelling economics to help expand our installed
 base beyond the 20% of the ENT offices that have already adopted Somnoplasty."
     The Elypse Control Unit continuously monitors and controls temperature,
 thereby preserving surface tissue and minimizing pain, bleeding and other
 complications.  Somnoplasty procedures can be performed using local anesthesia
 in an office or outpatient setting.  Patients enjoy a speedy recovery and
 often avoid the pain and inconvenience associated with traditional techniques.
 
     About the Somnoplasty System and Its Applications
     Somnus is pioneering a new standard of care for the treatment of upper
 airway disorders.  The Company's proprietary Somnoplasty System is the only
 temperature-controlled radiofrequency-based technology that has been
 previously cleared by the FDA for use in the treatment of chronic nasal
 obstruction and sleep disordered breathing-obstructive sleep apnea syndrome,
 upper airway resistance syndrome, habitual snoring, as well as a device for
 tissue coagulation in the head and neck.  The Somnoplasty procedures work by
 heating a targeted area of obstructive tissue below the surface.  The body
 naturally resorbs the heated area over a period of three to eight weeks
 reducing tissue volume. Clinical evaluations are underway to further expand
 the indications for the treatment of other upper airway obstructions.
 
     Forward-looking Statements
     This news release contains forward-looking statements that involve risks
 and uncertainties that could cause actual results or events to differ
 materially from those in such forward-looking statements.  Potential risks and
 uncertainties include, without limitation, the risks and uncertainties
 associated with the company's ability to accelerate revenue from handpiece
 sales, to increase physician interest in the use of TCRF for upper airway
 disorders and product acceptance and adoption, as well as those set forth in
 the company's latest annual report on Form 10-K, which is on file with the
 Securities and Exchange Commission.  Copies of the annual report on Form 10-K
 are available by calling the company's investor relations contact, Kay Hendrix
 408-617-3499.
 
     Somnus is headquartered in Sunnyvale, Calif. More information about Somnus
 and the Somnoplasty Procedure may be found at http://www.somnus.com and
 http://www.somnoplasty.com respectively .
 
     NOTE:  Somnus, Somnoplasty and the Somnus Medical Technologies logo are
 registered trademarks or service marks of Somnus Medical Technologies, Inc.
 
     Physician Information
      800-576-6687
     Ordering Information
      800-576-6687
 
 

SOURCE Somnus Medical Technologies Inc.
    SUNNYVALE, Calif., April 10 /PRNewswire/ --
 Somnus Medical Technologies Inc. (Nasdaq:   SOMN), announced today the
 availability of the Elypse Control Unit for the treatment of upper airway
 disorders.
     The Elypse Control Unit is another addition to the Somnoplasty(R)
 platform.  The new Control Unit delivers temperature-controlled radiofrequency
 energy to reduce and tighten tissue in the upper airway.  It is compatible
 with all existing Somnus single-channel handpieces.  In addition, the Control
 Unit has a compact new design.  Its small size makes it easy to transport
 between offices or treatment settings.  The Control Unit will be offered at a
 lower price than Somnus' existing two-channel Control Unit.
     "The new Elypse Control Unit is specifically designed for the office
 setting and should enable us to accelerate our penetration of this market
 segment," said John Schulte, President and CEO of Somnus Medical Technologies,
 Inc.  "It should provide compelling economics to help expand our installed
 base beyond the 20% of the ENT offices that have already adopted Somnoplasty."
     The Elypse Control Unit continuously monitors and controls temperature,
 thereby preserving surface tissue and minimizing pain, bleeding and other
 complications.  Somnoplasty procedures can be performed using local anesthesia
 in an office or outpatient setting.  Patients enjoy a speedy recovery and
 often avoid the pain and inconvenience associated with traditional techniques.
 
     About the Somnoplasty System and Its Applications
     Somnus is pioneering a new standard of care for the treatment of upper
 airway disorders.  The Company's proprietary Somnoplasty System is the only
 temperature-controlled radiofrequency-based technology that has been
 previously cleared by the FDA for use in the treatment of chronic nasal
 obstruction and sleep disordered breathing-obstructive sleep apnea syndrome,
 upper airway resistance syndrome, habitual snoring, as well as a device for
 tissue coagulation in the head and neck.  The Somnoplasty procedures work by
 heating a targeted area of obstructive tissue below the surface.  The body
 naturally resorbs the heated area over a period of three to eight weeks
 reducing tissue volume. Clinical evaluations are underway to further expand
 the indications for the treatment of other upper airway obstructions.
 
     Forward-looking Statements
     This news release contains forward-looking statements that involve risks
 and uncertainties that could cause actual results or events to differ
 materially from those in such forward-looking statements.  Potential risks and
 uncertainties include, without limitation, the risks and uncertainties
 associated with the company's ability to accelerate revenue from handpiece
 sales, to increase physician interest in the use of TCRF for upper airway
 disorders and product acceptance and adoption, as well as those set forth in
 the company's latest annual report on Form 10-K, which is on file with the
 Securities and Exchange Commission.  Copies of the annual report on Form 10-K
 are available by calling the company's investor relations contact, Kay Hendrix
 408-617-3499.
 
     Somnus is headquartered in Sunnyvale, Calif. More information about Somnus
 and the Somnoplasty Procedure may be found at http://www.somnus.com and
 http://www.somnoplasty.com respectively .
 
     NOTE:  Somnus, Somnoplasty and the Somnus Medical Technologies logo are
 registered trademarks or service marks of Somnus Medical Technologies, Inc.
 
     Physician Information
      800-576-6687
     Ordering Information
      800-576-6687
 
 SOURCE  Somnus Medical Technologies Inc.

RELATED LINKS

http://www.somnus.com